CDDW 2009 Abstracts TOC
Return to Main Menu
Search CDDW 2009 Abstracts
POSTER SESSION 2 - Immunology and Inflammatory Bowel Disease
165 - MMXTM MESALAMINE AND DELAYED-RELEASE MESALAMINE: A PHARMACOKINETIC AND SCINTIGRAPHIC COMPARISON
166 - METHOTREXATE IN THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: AN 8-YEAR RETROSPECTIVE STUDY ON 9...
167 - INCREASED ANTIGENIC UPTAKE IN PATIENTS WITH ULCERATIVE COLITIS - ROLE OF CRH AND MUSCARINIC REC...
168 - PREBIOTICS PREVENT LOSS OF INTESTINAL BIODIVERSITY AND REDUCE COLITIS IN HLA-B27 TRANSGENIC RAT...
169 - NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROMETRY METABOLOMIC URINE FINGERPRINT SEPARATES IBD FROM ...
170 - A MULTIDISCIPLINARY APPROACH TO CHARACTERIZING THE RELEASE PROFILES OF pH-DEPENDENT FORMULATION...
171 - FACTORS RELATING TO STEADY AND CONSISTENT RELEASE OF 5-AMINOSALICYLIC ACID (5-ASA) FROM ORAL pH...
172 - AUTOLOGOUS HEMATOPOETIC STEM CELL TRANSPLANTATION IN THE MANAGEMENT OF REFRACTORY CROHN'S...
173 - THE EFFECT OF NUTRITIONAL THERAPY ON GROWTH AND BONE MINERAL DENSITY IN THE TREATMENT OF PEDIAT...
174 - CORRELATION OF PLASMA SULFASALAZINE CONCENTRATION WITH INTESTINAL TRANSPORTER EXPRESSION
175 - LOWER BODY FAT COMPOSITION AND LOWER BODY MASS INDEX IS ASSOCIATED WITH CORTICOSTEROID USE AND ...
176 - INFLIXIMAB-INDUCED PSORIASIS IN PEDIATRIC CROHN DISEASE; EXPERIENCE OF THIS PARADOXICAL EVENT A...
177 - PHENOTYPIC VARIABLES ASSOCIATED WITH PROGRESSION OF DISEASE BEHAVIOUR IN CROHN'S DISEASE
178 - EXPRESSION AND FUNCTIONAL ANALYSIS OF INTESTINAL ORGANIC CATION/L-CARNITINE TRANSPORTER (OCTN) ...
179 - STRAIN DIFFERENCES IN THE SUSCEPTIBILITY TO DEXTRAN SODIUM SULFATE-INDUCED COLITIS IN MICE
180 - EARLY ONSET CROHN'S DISEASE IS ASSOCIATED WITH MALE GENDER AND A POLYMORPHISM IN THE IL6 ...
181 - EARLY AND SUSTAINED EFFICACY OF DELAYED-RELEASE ORAL MESALAMINE
182 - INCREASED EFFICACY OF DELAYED-RELEASE MESALAMINE 4.8G/D (800 MG TABLET) COMPARED TO 2.4G/D (400...
183 - RENAL EFFECTS OF LONG TERM 5-ASA
184 - SUSTAINED FISTULA HEALING IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE RECEIVING L...
185 - ADALIMUMAB MAINTAINS LONG-TERM REMISSION IN MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE...
186 - TIME TO SYMPTOM RESOLUTION IN PATIENTS WITH ULCERATIVE COLITIS: TREATMENT WITH MMXTM MESALAMINE...
187 - NALP SIGNALLING AND INNATE IMMUNE RESPONSES IN CLOSTRIDIUM DIFFICILE MEDIATED INTESTINAL INJURY
188 - ASSESSMENT OF THE ROLE OF INNATE IMMUNE RESPOSE AND NALP SIGNALLING IN INFLAMMATORY BOWEL DISEA...
189 - A POPULATION BASED STUDY OF BREASTFEEDING IN INFLAMMATORY BOWEL DISEASE: INITIATION, DURATION A...
190 - PROBIOTICS FOR INDUCTION OF REMISSION IN ULCERATIVE COLITIS
191 - BUTYRATE METABOLISM IN QUIESCENT ULCERATIVE COLITIS
192 - EFFECTS OF PROBIOTIC TREATMENT IN ENTEROCHROMAFFIN CELL FUNCTION, INFLAMMATION AND HOST DEFENSE...
193 - QUALITY OF LIFE (HEALTH-RELATED UTILITY) IN ADULTS WITH ULCERATIVE COLITIS IN REMISSION VS. MIL...
194 - ETHNIC VARIATION IN THE PREVALENCE OF ADULT INFLAMMATORY BOWEL DISEASE IN BRITISH COLUMBIA
195 - ROLE OF MAST CELLS AND PPAR-GAMMA IN EFFECTS OF PROBIOTICS ON INTESTINAL BARRIER TO E. COLI DUR...
196 - BUTYRATE PREVENTS THE TRANSLOCATION OF ESCHERICHIA COLI ACROSS EPITHELIA UNDER METABOLIC STRESS
197 - PREVALENCE OF MYCOBACTERIUM AVIUM PARATUBERCULOSIS IN PEDIATRIC INFLAMMATORY BOWEL DISEASE
198 - ENTERAL NUTRITION AS INDUCTION THERAPY FOR METASTATIC CROHN'S DISEASE
199 - RADIATION DOSES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
200 - PRESENCE OF ANTIBODIES IN SERUM OF CROHN'S DISEASE PATIENTS AGAINST SECRETED PROTEINS FRO...
201 - PREDICTORS OF MEDICATION ADHERENCE IN INFLAMMATORY BOWEL DISEASE PATIENTS AT THE STOLLERY CHILD...
202 - CERTOLIZUMAB PEGOL IS EFFECTIVE IN THE TREATMENT OF CROHN'S DISEASE PATIENTS WITH OPEN FI...
203 - PRELIMINARY INTERIM REPORT OF SERUM VITAMIN D LEVELS IN PATIENTS WITH IBD IN REMISSION AND THEI...
204 - IMPROVEMENT OF QUALITY OF LIFE IN PATIENTS WITH MODERATE ULCERATIVE COLITIS TREATED WITH DELAYE...
205 - LIFESTYLE EFFECTS ON INFLAMMATORY BOWEL DISEASES (LEIBD): PATIENT AWARENESS OF HOW SMOKING AFFE...
206 - EDUCATIONAL NEEDS ASSESSMENT IN CROHN'S DISEASE: MIXING METHODS TO UNCOVER GASTROENTEROLO...
207 - LINKING ENTERIC BACTERIA AND INTESTINAL BARRIER DYSFUNCTION TO THE PATHOGENESIS OF TYPE 1 DIABE...
208 - CITROBACTER RODENTIUM INFECTION IN NEONATAL MICE CAUSES DEATH: PROTECTION BY PROBIOTICS IS MEDI...
209 - THE EFFECT OF CONCOMITANT AZATHIOPRINE AND AMINOSALICYLATE USE IN PEDIATRIC INFLAMMATORY BOWEL ...
210 - DEFINING ANTIGEN SPECIFITY AND REQUIREMENT FOR T CELL RECEPTOR ACTIVATION OF T REG CELL SUPPRES...
211 - CERTOLIZUMAB PEGOL IS EFFICACIOUS IN CROHN'S DISEASE PATIENTS WHO HAVE FAILED INFLIXIMAB ...
212 - ESTIMATION OF INDUCTION AND MAINTENANCE COSTS OF INFLIXIMAB, ADALIMUMAB AND CERTOLIZUMAB PEGOL ...
213 - THE LONG-TERM, 30 MONTHS, EFFICACY AND TOLERABILITY OF CERTOLIZUMAB PEGOL THERAPY FOR CROHN'...
214 - IMPACT OF ONCE-DAILY VERSUS TWICE-DAILY MESALAZINE (PENTASA) ON RELIEF OF RECTAL BLEEDING AND S...
215 - SAFETY OF ONCE-DAILY VS TWICE-DAILY MESALAZINE (PENTASA®) DOSING. RESUTLS FROM A 12-MONTH RANDO...
216 - IMMUNOMODULATORY AND MUCIN ENHANCING EFFECT OF PROBIOTICS MIXTURE VSL#3 IN DSS INDUCED COLITIS
217 - DO PATIENTS WITH CROHN'S DISEASE HAVE AN INCREASED RISK OF CELIAC DISEASE?
218 - REGULATION OF P2Y2 RECEPTOR TRANSCRIPTION BY NFKB/P65 INDUCED BY PRO-INFLAMMATORY STIMULI IN IN...
219 - CORTICOTROPIN-RELEASING HORMONE, VASOACTIVE INTESTINAL PEPTIDE AND MAST CELLS MEDIATE ACUTE STR...
220 - GATA4 REGULATES THE INFLAMMATORY RESPONSE IN INTESTINAL EPITHELIAL CELLS
221 - INCREASING SMALL INTESTINAL PERMEABILITY EXACERBATES COLITIS IN THE IL-10 GENE DEFICIENT MOUSE
222 - COMPARISON OF ANII TNFalpha THERAPY OUTCOME BETWEEN MODERATELY SEVERE CROHN’S DISEASE AND ULCERATIVE COLITIS
223 - SMAD5 EXPRESSION IS MODULATED DURING EXPERIMENTAL COLITIS AND IBD
224 - THE EFFICACY, SAFETY AND TOLERABILITY OF METHOTREXATE FOR TREATING PATIENTS WITH CROHN'S ...